NasdaqGS:SVRABiotechs
A Look At Savara (SVRA) Valuation As MOLBREEVI Nears Key Regulatory Decisions In Rare Lung Disease
Savara (SVRA) is back in focus after regulators in Europe, the U.S. and the U.K. advanced reviews of its lead drug candidate MOLBREEVI for autoimmune pulmonary alveolar proteinosis, a rare chronic lung disease.
See our latest analysis for Savara.
At a share price of $5.46, Savara has seen an 8.12% 1 day share price return after the regulatory update, while its 1 year total shareholder return of 90.91% and 3 year total shareholder return of 219.30% signal strong longer term momentum despite...